Plasma cell myeloma
Not recruitingStudy Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant
- Disease:Plasma cell myeloma
- Substances:CarfilzomibLenalidomide+1
Italy- Participants:18–64 years · 65+ years
- Substances:Carfilzomib
- Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.








